Bienaime Jean Jacques's Form 4 filing
Biomarin Pharmaceutical IncBMRN · filed Jan 11, 2024
- Accession no.
- 0001048477-24-000002
- Filed
- Jan 11, 2024
- Trade date
- Jan 8-10, 2024
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.95M. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 8, 2024 | Common Stock | LLess common codeAcquired | +50 | $99.05 | +$4,952.5 | 425,162 | Direct | |
| Jan 9, 2024 | Common Stock | MOption exerciseAcquired | +10,000 | $63.10 | +$631,000 | 435,162 | Direct | |
| Jan 9, 2024 | Common Stock | SSaleDisposed | −10,000 | $98.19 | −$981,900 | 425,162 | Direct | |
| Jan 10, 2024 | Common Stock | MOption exerciseAcquired | +10,000 | $63.10 | +$631,000 | 435,162 | Direct | |
| Jan 10, 2024 | Common Stock | SSaleDisposed | −10,000 | $96.38 | −$963,800 | 425,162 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 9, 2024 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 171,000 | Direct | |
| Jan 10, 2024 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 161,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.